(Lung Cancer) Ensartinib Effective for ALK-Positive NSCLC with Brain Metastases

• April 10, 2017
• 1 min read

Ensartinib (X-396), a small-molecule compound with ALK inhibitory activity as well as activity against MET, ABL, Axl, EPHA2, LTK, ROS1, and SLK, has shown efficacy in ALK-positive advanced non-small cell lung cancer (NSCLC) with brain metastases.

Phase 1/2 study results were presented at the European Lung Cancer Conference (ELCC) 2017 in Geneva, Switzerland. The trial enrolled 30 patients with ALK-positive NSCLC with brain metastases who had progressed on prior ALK inhibitor therapy.

Results in brain metastases patients (N=30):

• Objective response rate (ORR): 40%
• Disease control rate (DCR): 87%

These results suggest that ensartinib may have meaningful intracranial activity in ALK-positive NSCLC patients with brain metastases who have progressed on prior ALK inhibitor therapy.

Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.

Source: ELCC 2017, Geneva

Lung Cancer | ALK-Positive | Brain Metastases

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4